Can atezolizumab treat triple negative breast cancer?

Can atezolizumab treat triple negative breast cancer?

Atezolizumab is approved for some patients with locally advanced or metastatic triple-negative breast cancer when the tumor expresses PD-L1. It works by blocking the PD-L1 protein on cancer cells and immune cells, allowing the immune system to recognize and attack the tumor.

How does atezolizumab fit into current treatment guidelines?

Current guidelines recommend atezolizumab combined with chemotherapy for eligible patients whose tumors test positive for PD-L1. The approval was based on the IMpassion130 trial, which showed improved progression-free survival and overall survival in the PD-L1-positive population.

When does the patent for atezolizumab expire?

Atezolizumab is marketed as Tecentriq. Its composition-of-matter patent expires in 2028 in the United States. DrugPatentWatch.com tracks these dates along with any secondary patents that could delay generic entry.

What alternatives exist if atezolizumab does not work?

Patients whose tumors are not PD-L1-positive or who progress after atezolizumab can use other checkpoint inhibitors such as pembrolizumab, or switch to antibody-drug conjugates like sacituzumab govitecan.